Search by Drug Name or NDC
NDC 69315-0506-09 DICLOFENAC POTASSIUM 50 mg/1 Details
DICLOFENAC POTASSIUM 50 mg/1
DICLOFENAC POTASSIUM is a ORAL POWDER, FOR SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Leading Pharma, LLC. The primary component is DICLOFENAC POTASSIUM.
MedlinePlus Drug Summary
Diclofenac capsules (Zipsor, Zorvolex) and tablets (Cataflam) are used to relieve mild to moderate pain. Diclofenac extended-release tablets (Voltaren XR), tablets (Cataflam), and delayed-release tablets (available generically) are used to relieve pain, tenderness, swelling, and stiffness caused by osteoarthritis (arthritis caused by a breakdown of the lining of the joints), and rheumatoid arthritis (arthritis caused by swelling of the lining of the joints). Diclofenac extended-release tablets and delayed-release tablets are also used to treat ankylosing spondylitis (arthritis that mainly affects the spine). Diclofenac tablets (Cataflam) are also used to treat painful menstrual periods. Diclofenac solution (Cambia) is used to treat migraine headaches in adults, but cannot be used to prevent migraines or to treat other types of headaches. Diclofenac is in a class of medications called NSAIDs. It works by stopping the body's production of a substance that causes pain, fever, and inflammation.
Related Packages: 69315-0506-09Last Updated: 02/19/2023
MedLinePlus Full Drug Details: Diclofenac
Product Information
| NDC | 69315-0506 |
|---|---|
| Product ID | 69315-506_9c24af27-0a21-4fb7-a8fb-55c92373b852 |
| Associated GPIs | |
| GCN Sequence Number | 068166 |
| GCN Sequence Number Description | diclofenac potassium POWD PACK 50 MG ORAL |
| HIC3 | H3F |
| HIC3 Description | ANTIMIGRAINE PREPARATIONS |
| GCN | 30891 |
| HICL Sequence Number | 008824 |
| HICL Sequence Number Description | DICLOFENAC POTASSIUM |
| Brand/Generic | Generic |
| Proprietary Name | DICLOFENAC POTASSIUM |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | DICLOFENAC POTASSIUM |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | POWDER, FOR SOLUTION |
| Route | ORAL |
| Active Ingredient Strength | 50 |
| Active Ingredient Units | mg/1 |
| Substance Name | DICLOFENAC POTASSIUM |
| Labeler Name | Leading Pharma, LLC |
| Pharmaceutical Class | Anti-Inflammatory Agents, Non-Steroidal [CS], Cyclooxygenase Inhibitors [MoA], Decreased Prostaglandin Production [PE], Nonsteroidal Anti-inflammatory Drug [EPC] |
| DEA Schedule | n/a |
| Marketing Category | NDA AUTHORIZED GENERIC |
| Application Number | NDA022165 |
| Listing Certified Through | 2025-12-31 |
Package
NDC 69315-0506-09 (69315050609)
| NDC Package Code | 69315-506-09 |
|---|---|
| Billing NDC | 69315050609 |
| Package | 9 PACKET in 1 CARTON (69315-506-09) / 1 POWDER, FOR SOLUTION in 1 PACKET |
| Marketing Start Date | 2022-12-20 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 29.056 |
| Pricing Unit | EA |
| Effective Date | 2024-02-21 |
| NDC Description | DICLOFENAC POT 50 MG POWDR PKT |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 1, 6 |
| Classification for Rate Setting | G |
| As of Date | 2024-02-21 |